Horizon Pharma (HZNP) Tops Q2 EPS by 17c, Revenues Beat; Offers FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Horizon Pharma (HZNP) PT Raised to $25 at Mizuho Securities
August 10, 2018 4:46 AM EDTMizuho Securities raised its price target on Horizon Pharma (NASDAQ: HZNP) to $25.00 (from $18.00) while maintaining a Buy rating.
... MoreHorizon Pharma (HZNP) PT Raised to $19 at BMO Capital
August 9, 2018 6:46 AM EDTBMO Capital raised its price target on Horizon Pharma (NASDAQ: HZNP) to $19.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Gary Nachman said solid 2Q results on the top and bottom line demonstrated good execution with its key growth drivers, including Krystexxa and... More
Horizon Pharma (HZNP) PT Raised to $25 at Cowen
August 8, 2018 10:02 AM EDTCowen raised its price target on Horizon Pharma (NASDAQ: HZNP) to $25.00 (from $24.00) while maintaining an Outperform rating.
Analsyt Ken Cacciatore said "Q2 came in above expectations and underlined a continued nice acceleration of the orphan assets, and was complimented by a consistent... More
BMO Capital Downgrades Horizon Pharma (HZNP) to Market Perform
August 6, 2018 5:10 AM EDTBMO Capital downgraded Horizon Pharma (NASDAQ: HZNP) from Outperform to Market Perform with a price target of $18.00.
ANalyst Gary Nachman comments "With the stock up ~30% since 1Q results and at our target, we're moving to the sidelines as we see risk/reward... More
